Although no existing monoclonal antibody therapy targets the IL-5 cytokine and its receptor in COPD, decreasing IL-5 may be effective in reducing the risk of exacerbation in patients with eosinophilic asthma30. The gene discussed is IL5; the disease is chronic obstructive pulmonary disease.